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In March 2010, the US Food and Drug Administration 
(FDA) approved the sustained release form of 4-amino-
pyridine (4-AP), Fampyra® (dalfampridine), for the 
treatment of walking difficulties in patients with multi-
ple sclerosis (MS). This drug improves gait speed in 
approximately 40% of MS patients.1 The active ingredi-
ent, 4-AP, is a reversible potassium-channel blocker 
used in experimental neurophysiology for decades; over 
the last years, a number of studies have shown that 4-AP 
has the ability to improve specific cerebellar dysfunc-
tions. In episodic ataxia type 2 (EA2), it prevents attacks 
and improves the patient’s quality of life.2 In two sepa-
rate cases with EA2, gait variability became reduced and 
the subjective fall risk decreased during treatment with 
4-AP.3 In patients with downbeat nystagmus syndrome 
secondary to cerebellar floccular dysfunction, the inten-
sity of nystagmus was reduced during treatment with 
4-AP.4 
Case report
Here we report a single case in which there was a positive 
effect of 4-AP treatment on upper limb tremors. A 44-year-
old woman with a progressive MS presented to the hospital 
with an Expanded Disability Status Scale (EDSS) score of 
6.5. Besides spastic-ataxic walking impairments, her major 
presentations were the presence of a postural and intention 
tremor of the upper extremities and the trunk, leading to a 
severe reduction of upper limb function, e.g. while brush-
ing her teeth or drinking a glass of water.
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Abstract
The reversible potassium channel blocker 4-aminopyridine is effective in the treatment of numerous cerebellar 
dysfunctions, such as episodic ataxia type 2 and downbeat nystagmus syndrome. In 2011, its sustained release form, 
dalfampridine, was admitted in Europe for the treatment of walking difficulties in patients with multiple sclerosis (MS).
Here we report the case of a 44-year old patient with a progressive MS whose upper limb tremor was markedly reduced 
under treatment with 4-aminopyridine, as documented in a Tremor Activities of Daily Living questionnaire and in the 
9-Hole Peg test. Hand accelerations decreased in the left hand from 10.9 m/sec2 to 2.2 m/sec2 and in the right hand from 
4.2 m/sec2 to 0.9 m/sec2.
This case report indicates for the first time that 4-aminopyridine might be effective in the symptomatic treatment of 
tremor entities in patients with MS. The finding calls for further prospective studies to determine the usefulness of 
4-aminopyridine or its sustained-release form dalfampridine in treating patients with tremor and MS.
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Assessment of the upper limb function included the 9-Hole 
Peg test. The time for completion of this test was 75 s, with the 
right hand. The test could not be completed by the patient with 
her non-dominant left hand. On a questionnaire-based tremor 
scale of activities of daily living, she rated 89 out of a maximum 
of 100 points. Tremor analysis using the Noraxon® system was 
performed using a surface electromyography (EMG) over bilat-
eral antagonistic muscles, as well as 3-dimensional (3-D) accel-
erometers that were mounted bilaterally, at the dorsal surface of 
both hands. The accelerometer and EMG recordings were per-
formed under the condition of holding the upper limbs against 
gravity, in a sitting position. Tremor intensity was calculated 
using a standard 3-D root mean square analysis. Her tremor 
intensities (hand accelerations) were 10.89 m/s2 for the left hand 
and 4.23 m/s2 for the right hand, with a frequency of 3.0 to 3.4 
s–1 (see Video 1, in the supplemental data). 
The patient was symptomatically treated with 4-AP (5 mg 
t.i.d.). Only 24 hours after the first administration, the patient 
reported there had been an improvement of her arm and hand 
tremors. Subjective scoring of the tremor-related activities 
of daily living improved from 89 to 77 points. With her dom-
inant right hand, she completed the 9-Hole Peg test within 
56s (a reduction of 19 s). Completion of the 9-Hole Peg test 
with her left hand was still not possible. After 62 h of treat-
ment, the accelerometer recordings and video analysis were 
repeated, revealing a marked decrease in tremor intensity 
(see Video 1, supplemental data). Hand acceleration 
decreased by approximately 80% (left hand: reduction from 
10.9 m/s2 to 2.2 m/s2; right hand: reduction from 4.2 m/s2 to 
0.9 m/s2). Surface-EMG recordings showed a reduction of 
both distal and proximal arm muscle activity (for proximal 
muscles, see Figure 1). The frequency of the tremor remained 
unaffected.
Besides the effect on the hand tremors, the patient’s gait 
performance (gait speed, stride length, gait variability) 
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Figure 1. Surface EMG recordings of the left proximal muscles.
(a) Compounding action potentials of the left arm over a 5-s time period, under the condition of holding, before 4-AP therapy;
(b) Compounding action potentials of the left arm over a 5-s time period, under the condition of holding, under the influence of 4-AP therapy.
4-AP: 4-aminopyridine; EMG: electromyography.
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After a follow-up period of 4 weeks, all improvements 
in subjective, clinical and neurophysiological measure-
ments remained stable (data not shown). The patient is con-
tinuing the 4-AP treatment, which has lasted for more than 
18 months now. She has refused to switch her medication 
from 4-AP to dalfampridine, citing both its beneficial 
effects and an absence of side effects.
Discussion
The symptomatic treatment of MS patients with 
cerebellar tremor remains a challenge for clinicians. 
Pharmacotherapeutic  strategies are described in several 
small, short-duration studies5,6 but evidence is conflicting. 
Deep brain stimulation, mainly of the ventral intermediate 
thalamic nuclei, may obtain tremor reduction, but this is 
associated with potentially serious side effects.7
This case report indicates for the first time the usefulness 
of 4-AP in improving the upper limb tremor of a MS patient. 
Thus, besides its positive effect on walking performance in 
MS patients, 4-AP may also be considered as a new option 
for the symptomatic treatment of tremor in patients with MS.
Aminopyridines were previously tested in the sympto-
matic treatment of tremor patients. A prospective, double-
blinded cross-over trial with 3,4-diaminopyridine in 19 
patients with essential tremor did not show any positive 
effects.8 Our case report indicates that aminopyridines may 
be effective in treating MS tremor, secondary to patholo-
gies of the cerebellum. Our patient showed a high burden 
of disease within the cerebellum and cerebellar peduncles 
(Figure 2). Clinical testing revealed a marked cerebellar 
ataxia and the criteria for a cerebellar tremor (low fre-
quency, postural and intention tremor) were fulfilled.
Supported by animal studies, the putative mode of action 
of 4-AP on cerebellar functions is thought to be an improve-
ment of Purkinje cell function. The drug 4-AP improves the 
excitability and the precision of cerebellar Purkinje cells.9 
Moreover, 4-AP reduces the excitability of olivary neurons, 
at least in the guinea pig, which in turn are thought to be the 
rhythm pacemakers in the harmaline-induced tremor model.10
Taking these findings into account, one can argue that 
4-AP may have the potential to improve any tremor entities 
that are linked to cerebellar dysfunctions. This further 
implies that our observation should encourage us to further 
investigate the usefulness of 4-AP, or its sustained release 
formulation dalfampridine; in a systemic, controlled trial in 
patients with MS tremor, especially when cerebellar symp-
toms are present.
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Figure 2. T2 sequences of the brain of the patient, prior to 
treatment, using a Siemens® MRI Scanner at 1.5 Tesla.
(a) T2 (3mm) sequence of the cerebellum, inferior cerebellar peduncles 
and brainstem
(b) T2 (3mm) sequence of the cerebellum, middle cerebellar peduncles 
and brainstem
(c) T2 (3mm) sequence of the inferior thalamus
MRI: magnetic resonance imaging;
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